<DOC>
	<DOCNO>NCT01173471</DOCNO>
	<brief_summary>The purpose study evaluate efficacy systemically administer AZD4017 , compare placebo , 28-day period patient raise intra-ocular pressure ( IOP ) .</brief_summary>
	<brief_title>A Phase IIa Study Assess Tolerability , Safety , Efficacy AZD4017 Raised Intra-ocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Must diagnosis intraocular hypertension ( raise IOP ) , primary openangle glaucoma ( POAG ) , IOP &gt; 20 mmHg ≤36 mmHg study eye , currently prescribe stable dose single antiglaucoma medication begin least 30 day prior screen visit ; OR Must diagnosis intraocular hypertension ( raise IOP ) , define IOP ≥22 mmHg ≤36 mmHg study eye antiglaucoma medication Male patient must willing use barrier contraception spermicide , ie , condom , day first dose 3 month dose IP Placebo treatment duration study must consider detrimental patient Have uncontrolled intraocular hypertension ( &gt; 36 mmHg ) Have experience significant visual field loss show evidence progressive visual field loss within last year ( define &gt; 1 dB/yr average loss vision threaten new defect ) Have severe eye trauma time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Raised intraocular pressure</keyword>
</DOC>